BioCentury
ARTICLE | Clinical News

ADI-PEG 20: Phase II started

November 11, 2013 8:00 AM UTC

Polaris began an open-label Phase II trial to evaluate ADI-PEG 20 in about 21 patients with relapsed and/or refractory AML. ADI-PEG 20 is in a Phase III trial under an SPA from FDA to treat hepatocell...